[1]
Reggio P.H.: The Cannabinoid Receptors. Humana Press, c/o Springer
Science & Business Media, LLC 2009.
[2]
Hall W., Room R., Bondy S.: WHO project on health implication of cannabis
use: a comparative appraisal of the health and psychological consequences
of alcohol, cannabis, Nicotine and Opiate Use, August 28: 1995.
[3]
Baselt R.C.: Disposition of toxic drugs and chemicals in man. Biomed
Publ 2011: 1644–1648.
[4]
Lachenmeier D.W., Rehm J.: Comparative risk assessment of alcohol,
tobacco, cannabis and other illicit drugs using the margin of exposure
approach. Sci Reports 2015; 5: 1–7.
[5]
Johnson M., Devane W., Howlett A., et al.: Structural studies leading to
the discovery of a cannabinoid binding site. NIDA Research Monograph
1988; 90: 129–135.
[6]
Howlett C.A., Barth F., Bonner T., et al.: International Union of
Pharmacology. XXVII. Classification of cannabinoid receptors. Pharm
Rev 2002; 54 (2): 161–202.
[7]
Pertwee R.G.: The pharmacology of cannabinoid CB1 and CB2 receptors.
Pharmacology & Therapeutics 1997; 74: 129–180.
[8]
Deutsch D.G., Chin S.A.: Enzymatic synthesis and degradation of
anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993;
46: 791–796.
[9]
Leweke F.M., Piomelli P., Fahlish F.: Cannabidiol enhances anandamide
signaling and alleviates psychotic symptoms of schizophrenia. Trans
Psychiatry 2012; 2: 94.
[10]
Sugiura T., Waku K.: 2-Arachidonoylglycerol and the cannabinoid
receptors. Chem Phys Lipids 2000; 108: 86–106.
[11]
Darmani N.A.: The potent emetogenic effects of the endocannabinoid, 2-AG
(2-arachidonoylglycerol) are blocked by Δ9-tetrahydrocannabinol and
other cannabinoids. J Pharmacol Exper Ther 2002; 300: 34–42.
[12]
Ryberg E., Larsson N., Sjörgen S., et al.: The orphan receptor GPR55 is
a novel cannabinoid receptor. Brit J Pharamcol 2007; 152: 1092–1101.
[13]
Russo E.B., Burnett A., Hall B., et al.: Agonistic properties properties of
cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30: 1037–1043.
[14]
Bisogno T., Hanus L., De Petrocelis L., et al.: Molecular targets for
cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors
and on the cellular uptake and enzymatic hydrolysis of anandamide. Brit
J Pharmacol 2001; 134: 845–852.
[15]
Katona B., Sperlagh A., Sik A., et al.: Presynaptically located CB1
cannabinoid receptors regulate GABA release from axon terminals of
specific hippocampal interneurons. J Neurosci 1999; 19: 454–458.
[16]
Ryan D., Drysdale A.J., Lafourcade C., et al.: Cannabidiol targets
mitochondria to regulate intracellular Ca+2 levels. J Neurosci 2009; 29:
2053–2063.
[17]
Foldy C., Neu A.V., Jones J., et al.: Presynaptic, activity-dependent
modulation of cannabinoid type 1 receptor-mediated inhibition of GABA
release. J Neurosci 2006; 26: 1465–1469.
[18]
During M.J., Spencer D.D.: Adenosine: a potential mediator of seizure
arrest and postictal refractoriness. Ann Neurol 1992; 32: 618–624.
[19]
Hussain S.A.: Perceived efficacy of cannabidiol-enriched cannabis
extracts for treatment of pediatric epilepsy: A potential role for infantile
spasms and Lennox-Gastaut syndrome. Epilepsy & Behavior 2015; 47:
138–141.
[20]
Karniol I.G., Shirakawa I., Kasinski N., et al.: Cannabidiol interferes with
the effects of delta-9-tetrahydrocannabinol in man. Eur J Pharmacol
1974; 28: 122–127.
[21]
Dalton W.S., Martz R., Lemberger L., et al.: Influence of cannabidiol on
delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 1976; 19:
300–309.
[22]
Grifith-Lendering M.F., Wigman J.T., Prince van Leeuven A., et al.:
Cannabis use and vulnerability for psychosis in early adolescence –
a trails study. Addiction 2013; 108: 733–740.
[23]
Fontes M.A., Bolla K.J., Cunha P.J., et al. Cannabis use before 15 age and
subsequent executive functioning. Brit J Psychiatr 2011; 198: 442–447.
[24]
Pertwee R.G.: The diverse CB1 and CB2 receptor pharmacology of
three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and
Δ9-tetrahydrocannabivarin, Brit J Psychiatr 2008; 153: 199–215.
[25]
Hill A.J., Williams C.M., Whally B.J., et al.: Phytocannabinoids as novel
therapeutic agents in CNS disorders. Pharmacol Ther 2012; 133: 79–97.
[26]
GW Pharmaceuticals Initiates Phase 2 Clinical Study of Cannabidivarin
(CBDV) in Epilepsy, London UK, 6 may 2015 GW.
[27]
Cunha J.M., Carlini E.A., Pereira A.E., et al.: Chronic administration of
cannabidiol to healthy volunteers and epileptic patients. Pharmacology
1980; 21: 175–185.
[28]
Zuardi A.W., Crippa J.A., Hallak J.E. et al.: Cannabidiol, a Cannabis
sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;
39(4): 421–429.
[29]
Zuardi A.W.: Cannabidiol: from an inactive cannabinoid to a drug with
wide spectrum of action. Rev Bras Psiquiatr 2008; 30(3): 271–280.
[30]
Bergamaschi M.M., Queiros R.H.C., Crippa J.A.S., et al.: Safety and
side effects of Cannabidiol, a Cannabis sativa constituent. Current Drug
Safety 2011; 6: 1–13.
[31]
Perez-Reyes M., Timmons M.C., Davis K.H., et al.: A comparison of the
pharmacological activity in man of intravenously administered delta-9-
tetrahydrocannabinol, cannabinol and cannabidiol. Experientia 1973; 29:
1368–1369.
[32]
Hollister L.E.: Cannabidiol and cannabinol in man. Experientia 1973; 29:
825–826.
[33]
Zuardi A.W., Shirakawa I., Finkelfarb E., et al.: Action of cannabidiol on
the anxiety another effects produced by delta 9-THC in normal subjects.
Psychopharmacology (Berl) 1982; 76: 245–250.
[34]
Mincis M., Pfeferman A., Guimarães R.X., et al.: Chronic administration
of cannabidiol in man. Pilot study. AMB Rev Assoc Med Bras 1973;
19(5): 185–190.
[35]
Szaflarski J.P., Bebin E.M.: Cannabis, cannabidiol and epilepsy – from
receptors to clinical response. Epilepsy & Behavior 2014; 41: 277–282.
[36]
Devinsky O., Cilio M. R., Cross H., et al.: Cannabidiol: pharmacology
and potential therapeutic role in epilepsy and other neuropsychiatric
disorders. Epilepsia 2014; 55(6): 791–802.
[37]
Devinsky O.: Commentary: medical marijuana survey and epilepsy.
Epilepsia 2015; 56:7–8.
[38]
Porter B.E., Jacobson C.: Report of a parent survey of cannabidiol
– enriched cannabis use in pediatric treatment – resistant epilepsy.
Epilepsy and Behavior 2013; 29: 574–577.
[39]
Detyniecki K., Hirsch L.: Marijuana use in epilepsy: the myth and reality.
Curr Neurol Neurosci Rep 2015; 65: 1–6.
[40]
Indorato F., Liberto A., Ledda C., et al.: The therapeutic use of
cannabinoids: forensic aspects. Forencic Sci Int 2016; 265: 200–203.
[41]
Gloss D., Vickrey B.: Cannabinoids for epilepsy. Cochrane Data Base
Syst Rev 2012; 6: CD009270.
[42]
Press C.A., Knupp K.G., Chapman K.E.: Parental reporting of response to
oral cannabis extracts for treatment of refractory epilepsy. Epilepsy &
Behavior 2015; 45: 49–52.
[43]
Makulec A., Lasoń W., Jóźwiak S.: Marijuana derivates in epilepsy
treatment in childhood – currenet knowledge. Pediatr Pol 2016; 91(6):
574–580.
[44]
Thiele E., Mazurkiewicz-Beldzińska M., Benbadis S., et al.: Cannabidiol
(CBD) significantly reduces drop seizure frequency in Lennox-Gastaut
syndrome: results of a multi-center, randomized, double-blind, placebocontrolled
trial (GWPCARE4). 70 American Epilepsy Society Annual
Meeting, Dec. 2–6, 2016, Houston.
[45]
Cross J.H., Devinsky O., Laux L., et al.: Cannabidiol (cbd) reduces
convulsive seizure frequency in dravet syndrome: results of a multicentered,
randomized, controlled study (GWPCARE1). 70 American
Epilepsy Society Annual Meeting, Dec. 2–6, 2016, Houston.
[46]
Treat L., Chapman K.E., Colborn K.L., et al.: Duration of use of oral
cannabis extract in a cohort of pediatric epilepsy patients. Epilepsia
2017; 58(1): 123–127.
[47]
Wade D.T., Makela P., Robson P., et al.: Do cannabis-based medicinal
extracts have general or specific effects on symptoms in multiple
sclerosis? A double-blind, randomized, placebo-controlled study on 160
patients. Mult Scler 2004; 10(4): 434–441.
[48]
Consroe P., Laguna J., Allender J., et al. Controlled clinical trial of
cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 1991;
40(3): 701–708.
[49]
Jones G., Pertwee R.G.: A metabolic interaction in vivo between
cannabidiol and 1-tetrahydrocannabinol. Brit J Pharmacol 1972; 45(2):
375–377.
[50]
Paton W.D.M., Pertwee R.G.: Effect of cannabis and certain of its
constituents on pentobarbitone sleeping time and phenazone
metabolism. Brit J Pharmacol 1972; 44: 250–261.
[51]
Jaeger W., Benet L.Z., Bornheim L.M.: Inhibition of cyclosporine and
tetrahydrocannabinol metabolism by cannabidiol in mouse and human
microsomes. Xenobiotica 1996; 26(3): 275–284.
[52]
Guengerich F.P. [in :] Ortiz de Montellano P.R., Ed. Cytochrome P450:
Structure, Mechanism and Biochemistry. New York: Plenum Press.
1995; 473–535.
[53]
Bornheim L.M., Correia M.A.: Selective inactivation of mouse liver
cytochrome P-4501IIA by cannabidiol. Mol Pharmacol 1990; 38: 319–
326.
[54]
McKallip R.J., Jia W., Schlomer J., et al.: Cannabidiol-induced apoptosis
in human leukemia cells: a novel role of cannabidiol in the regulation of
p22phox and Nox4 expression. Mol Pharmacol 2006; 70: 897–908.
[55]
Lee C.Y., Wey S.P., Liao M.H., et al.: A comparative study on cannabidiolinduced
apoptosis in murine thymocytes and EL-4 thymoma cells. Int
Immunopharmacol 2008; 8(5): 732–740.
[56]
Ustawa z dnia 6 września 2001 roku – Prawo Farmaceutyczne Dz. U.
z 2008 roku, Nr 45, poz. 271 z późniejszymi zmianami.
[57]
Ustawa z 5 grudnia 1996 r. o zawodach lekarza i lekarza dentysty Dz. U.
Nr 28, poz. 152 z późniejszymi zmianami.
[58]
Miastkowska-Daszkiewicz K.: Prawne aspekty produktów leczniczych
stosowanych w populacji pediatrycznej. Medyczna Wokanda NIL-WIL
2009;1: 95–108.
[59]
Zoll A.: Problemy teoretyczne struktury przestępstwa. Podstawy
regulacji w nowym kodeksie karnym. [w:] Wolf G. (red.): Przestępczość
przygraniczna. T. II, Nowy kodeks karny. Coll. Polonicum, Frakfurt (Oder),
Słubice, Poznań, 2003: 27.
[60]
Tymiński R.: Stosowanie leków poza wskazaniami zawartymi
w charakterystyce produktu leczniczego. Med Prakt 2012, Prawo.mp.pl
2012: 1–3.
[61]
Paszkiewicz J.: Stosowanie leków poza wskazaniami leczniczymi.
Eksperyment. Menedżer Zdrowia 2006; 8: 42–44.
[62]
Zajdel J., Zajdel R.: Czy import docelowy zależy od swobodnej decyzji
lekarza, Standardy Med Pediatria 2009; 6(5): 839–843.
[63]
Machalski P.: Doktor od marihuany wygrał z CZD. Gazeta Wyborcza,
15.09.2016.
[64]
Wachowiak J., Krawczyński M.: Niektóre aktualne prawne i klinicznonaukowe
aspekty farmakoterapii w pediatrii i onkologii dziecięcej.
Pediatr Pol 2016; 91(3): 185–191.
[65]
Mathern G.W., Beninsig L., Nehlig A.: Fewer specialists support using
medical marijuana and CBD in treating epilepsy patients compared with
other medical professionals and patients: result of Epilepsia’s survey.
Epilepsia 2015; 56(1): 1–6.
[66]
Steinborn B.: Standardy postępowania w schorzeniach układu
nerwowego u dziecii młodzieży. Bifolium, Lublin 2015.
[67]
Committee on Substance Abuse, COA: The Impact of Marijuana Policies
on Youth: Clinical, Research and Legal Update. Pediatrics 2015; 135(3):
584–587.
[68]
AES Position on Medical Meijuana. www.AESNET.org, Febr. 28, 2014.
[69]
Stanowisko Polskiego Towarzystwa Neurologów Dziecięcych dotyczące
stosowania pochodnych Cannabis sativa w leczeniu dzieci i młodzieży.
[w:] Standardy postępowaniaw schorzeniach układu nerwowego
u dzieci i młodzieży. Bifolium, Lublin 2015.
[70]
Stanowisko Zarządu Głównego Polskiego Towarzystwa Epileptologii
(PTE) w sprawie leczenia padaczki produktami na bazie marihuany.
[w:] Zalecenia Polskiego Towarzystwa Epileptologii dotyczące napadów
padaczkowych u dorosłych (Jędrzejczak i wsp. 2014).
[71]
Piechocki A.: Tylko Sativex. Biul Inf WIL 2016; 10(261): 23.
[72]
Piechocki A.: Charakter eksperymentalny. Biul Inf WIL 2016; 10(261): 23.
[73]
Czupryn A.: Tomasz Kalita walczył o leczniczą marihuanę. Głos Wlkp.
Nr 16, s. 34
[75]
Żbikowska M.: Pacjenci nie chcą odlotu. Domagają się leku, który
uśmierzy ich cierpienie. Głos Wlkp. Nr 22, s. 14–15, 27.01.2017.
Scholar Google
PubMed